These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 25341712)

  • 21. High clopidogrel dose in patients with chronic kidney disease having clopidogrel resistance after percutaneous coronary intervention.
    Liang J; Wang Z; Shi D; Liu Y; Zhao Y; Han H; Li Y; Liu W; Zhang L; Yang L; Zhou Y
    Angiology; 2015 Apr; 66(4):319-25. PubMed ID: 24913197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.
    Tada T; Byrne RA; Simunovic I; King LA; Cassese S; Joner M; Fusaro M; Schneider S; Schulz S; Ibrahim T; Ott I; Massberg S; Laugwitz KL; Kastrati A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1267-74. PubMed ID: 24355117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. COURAGE or FAME...? Who should have percutaneous coronary intervention in stable coronary artery disease?
    Fox KA
    Heart; 2013 Apr; 99(7):442-4. PubMed ID: 23086969
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term risk of late and very late stent thrombosis in patients treated with everolimus against paclitaxel-eluting stents: an updated meta-analysis.
    Li P; Liu JP
    Coron Artery Dis; 2014 Aug; 25(5):369-77. PubMed ID: 24818639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K; Niemelä M; Romppanen H; Erglis A; Kumsars I; Maeng M; Holm NR; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Helqvist S; Vikman S; Wiseth R; Aarøe J; Jokelainen J; Thuesen L;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1160-5. PubMed ID: 24262616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
    Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stenting: the Latest Frontier in Percutaneous Intervention.
    Kleiman N
    Methodist Debakey Cardiovasc J; 2018; 14(1):5-6. PubMed ID: 29623166
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of 5-year outcomes in patients with and without unprotected left main coronary artery disease after treatment with sirolimus-eluting stents: insights from the j-Cypher registry.
    Toyofuku M; Kimura T; Morimoto T; Hayashi Y; Shiode N; Nishikawa H; Nakao K; Shirota K; Kawai K; Hiasa Y; Kadota K; Nozaki Y; Isshiki T; Sone T; Mitsudo K;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):654-63. PubMed ID: 23866178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting.
    Breet NJ; de Jong C; Bos WJ; van Werkum JW; Bouman HJ; Kelder JC; Bergmeijer TO; Zijlstra F; Hackeng CM; Ten Berg JM
    Thromb Haemost; 2014 Dec; 112(6):1174-81. PubMed ID: 25231776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Coronary artery bypass grafting is superior to first-generation drug-eluting stents for unprotected left main coronary artery disease: an updated meta-analysis of 4 randomized, controlled trials.
    Benedetto U; Ng C; Smith R; Raja SG;
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2430-2. PubMed ID: 25224547
    [No Abstract]   [Full Text] [Related]  

  • 32. Polymeric bioresorbable coronary scaffolds: the hype is over, but the dream lives on.
    Pyxaras SA; Wijns W
    EuroIntervention; 2018 Jan; 13(13):1506-1509. PubMed ID: 29345240
    [No Abstract]   [Full Text] [Related]  

  • 33. Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients.
    Lupi A; Rognoni A; Secco GG; Lazzero M; Nardi F; Fattori R; Bongo AS; Agostoni P; Sheiban I
    Eur J Prev Cardiol; 2014 Apr; 21(4):411-24. PubMed ID: 23152364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Six-year clinical outcomes of first-generation drug-eluting stents: a propensity-matched analysis.
    Tarantini G; Barioli A; Facchin M; Frigo AC; Napodano M; Buja P; D'Amico G; Iliceto S; Isabella G
    Coron Artery Dis; 2013 Aug; 24(5):440-8. PubMed ID: 23695366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The independent value of a direct stenting strategy on early and late clinical outcomes in patients undergoing elective percutaneous coronary intervention.
    Sardi GL; Laynez-Carnicero A; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Catheter Cardiovasc Interv; 2013 May; 81(6):949-56. PubMed ID: 22888029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies.
    Zimarino M; Corazzini A; Ricci F; Di Nicola M; De Caterina R
    JACC Cardiovasc Interv; 2013 Jul; 6(7):687-95. PubMed ID: 23769650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Personalized antiplatelet therapy: the wrong approach?
    Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2013 Oct; 106(10):481-6. PubMed ID: 24080323
    [No Abstract]   [Full Text] [Related]  

  • 38. Exercise training is safe after coronary stenting: a prospective multicentre study.
    Iliou MC; Pavy B; Martinez J; Corone S; Meurin P; Tuppin P;
    Eur J Prev Cardiol; 2015 Jan; 22(1):27-34. PubMed ID: 24057686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis?
    Lemos PA
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):959-60. PubMed ID: 17525956
    [No Abstract]   [Full Text] [Related]  

  • 40. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.